Technology | September 29, 2014

AliveCor Launches New App to Auto-Detect Atrial Fibrillation on a Smartphone

Additional new features help patients and physicians monitor and manage heart health

alivecore, alivercor, smartphone ECG, AF, Afrib, atrial fibrillation

September 29, 2014 — AliveCor announced the launch of the latest version of the AliveECG app, which provides patients with free real-time atrial fibrillation (AF) detection in electrocardiogram (ECG) recordings using its new U.S. Food and Drug Administration (FDA) -cleared algorithm. The new app helps patients and physicians manage existing conditions with intelligent, personalized and easy-to-use new features. Tracking of medications, lifestyle choices and ongoing symptoms allows patients to have a better understanding of their health status. Advanced search features and enhanced graphical trends provide a more comprehensive and reliable view of a patient's overall health.

The AliveECG app and the AliveCor Heart Monitor can be used to capture ECGs anytime, anywhere with no time limit. This is in contrast to traditional heart monitors, which have a maximum recording window of 30 days, uncomfortable leads and no immediate display. Patients can log their symptoms, activities and medications, and work together with physicians to determine the cause of symptoms in a simple and affordable manner. The AliveECG app also helps inform clinical decision-making through immediate detection of AF and patient engagement through tracking medications, symptoms and lifestyle activities.

"With AliveCor's new app my patients can forgo pulse monitoring and paper-based logging which is often unreliable and incomplete," said Jonathan Steinberg, M.D., director, Arrhythmia Institute Valley Health System, adjunct professor of medicine, University of Rochester School of Medicine. "When working with patients with suspected or diagnosed heart conditions, the AliveECG app assists me in determining which medications, habits and activities are truly impacting their heart health. I now have a more complete view about what is happening between appointments and can even give immediate advice about what to do next during an AF episode."

"The national incremental cost of AF is approximately $26 billion; therefore it is our continued focus to help reduce the burden of AF on the healthcare system. We offer patients an efficient way to manage and track their heart heath," said Euan Thomson, president and CEO at AliveCor. "The new AliveECG app makes significant strides in providing both patients and caregivers mobile health technology with clinical quality ECGs and analysis to improve heart health."

The AliveCor Heart Monitor is intended to record, store and transfer ECG rhythms. The AliveCor Heart Monitor also displays ECG rhythms and detects the presence of AF when prescribed or used under the care of a physician. The AliveCor Heart Monitor is intended for use by healthcare professionals, patients with known or suspected heart conditions and health conscious individuals. It is available for iOS users only; a new version of the Android app with the AF Detector enabled will be available in October. The AliveCor Heart Monitor is compatible with all iOS models and most Android mobile devices. Users will continue to have the ability to access their data confidentially anytime, anywhere.

For more information: www.alivecor.com

Related Content

Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

Feature | Left Atrial Appendage (LAA) Occluders| September 07, 2017
September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to
Text Messaging Could Help Tackle High Blood Pressure in At-Risk Patients

Image courtesy of Michigan Medicine

News | Hypertension| September 06, 2017
A new National Institutes of Health-funded hypertension trial will examine the possibility of using an emergency...
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices

Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices.

Feature | EP Lab| August 29, 2017 | Dave Fornell
August 29, 2017 — The U.S.
Real-World Analysis Compares Safety, Effectiveness of Apixaban Versus Warfarin
News | Antiplatelet and Anticoagulation Therapies| August 28, 2017
August 28, 2017 — Bristol-Myers Squibb Company and Pfizer Inc.
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Overlay Init